Company intelligence / Profile preview

Fitlens

Ownership: Private
Development stage: Commercial

Overview

Fitlens acts as a distributor for advanced ophthalmic digital therapeutics and diagnostic devices in China. It has partnered with NovaSight to distribute CureSight, an FDA-, CE-, and NMPA-approved digital treatment for amblyopia. The company also plans to distribute TrackSight®, an AI-based application for myopia control. No proprietary clinical results or internal pipeline data are publicly available as of the latest updates.

Therapeutic areas: Ophthalmology
Modalities: Device (specifically ophthalmic/vision care devices)
Industry: Digital Health Medical Devices

Partnerships

NovaSight (distribution partnership for CureSight and TrackSight® in China)

Beyond the preview

Go deeper on Fitlens.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fitlens.

Explore the full profile